A recent study showed that treatment with SK609, a selective dopamine D3 receptor (D3R) agonist and norepinephrine transporter (NET) inhibitor, alleviated motor symptoms and improved cognitive task performance in in vivo PD models without causing side effects associated with dopamine transporter activity [5]. The gene discussed is SLC6A2; the disease is Parkinson disease.